Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma.

Fu Q, Chen M, Hu S, McElroy CA, Mathijssen RH, Sparreboom A, Baker SD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:43-51. doi: 10.1016/j.jchromb.2018.05.005. Epub 2018 May 5.

PMID:
29783173
2.

Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia.

van Oosterwijk JG, Buelow DR, Drenberg CD, Vasilyeva A, Li L, Shi L, Wang YD, Finkelstein D, Shurtleff SA, Janke LJ, Pounds S, Rubnitz JE, Inaba H, Pabla N, Baker SD.

J Clin Invest. 2018 Jan 2;128(1):369-380. doi: 10.1172/JCI91893. Epub 2017 Dec 11.

3.

Variability of Capillary Refill Time among Physician Measurements.

Sheridan DC, Baker SD, Kayser SA, Jones D, Hansen ML.

J Emerg Med. 2017 Nov;53(5):e51-e57. doi: 10.1016/j.jemermed.2017.06.035. Epub 2017 Sep 21.

PMID:
28941555
4.

Kinase Inhibitors: The Reality Behind the Success.

Jeon JY, Sparreboom A, Baker SD.

Clin Pharmacol Ther. 2017 Nov;102(5):726-730. doi: 10.1002/cpt.815.

PMID:
28795397
5.

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.

Hu S, Mathijssen RHJ, de Bruijn P, Baker SD, Sparreboom A.

Br J Cancer. 2017 Aug 22;117(5):e3. doi: 10.1038/bjc.2017.217. Epub 2017 Jul 13.

6.

Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity.

Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens J, Baker SD, Pabla N, Sparreboom A.

Clin Transl Sci. 2017 Sep;10(5):412-420. doi: 10.1111/cts.12480. Epub 2017 Jul 8.

7.

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.

Jarusiewicz JA, Jeon JY, Connelly MC, Chen Y, Yang L, Baker SD, Guy RK.

ACS Omega. 2017 May 31;2(5):1985-2009. doi: 10.1021/acsomega.7b00144. Epub 2017 May 10.

8.

Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.

Karol SE, Yang W, Smith C, Cheng C, Stewart CF, Baker SD, Sandlund JT, Rubnitz JE, Bishop MW, Pappo AS, Jeha S, Pui CH, Relling MV.

Cancer. 2017 Sep 15;123(18):3602-3608. doi: 10.1002/cncr.30762. Epub 2017 May 11.

PMID:
28493546
9.

A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).

Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26414. Epub 2017 Apr 14.

PMID:
28409853
10.

Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.

Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD.

Clin Transl Sci. 2017 Jul;10(4):271-279. doi: 10.1111/cts.12458. Epub 2017 Mar 31.

11.

OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.

Drenberg CD, Gibson AA, Pounds SB, Shi L, Rhinehart DP, Li L, Hu S, Du G, Nies AT, Schwab M, Pabla N, Blum W, Gruber TA, Baker SD, Sparreboom A.

Cancer Res. 2017 Apr 15;77(8):2102-2111. doi: 10.1158/0008-5472.CAN-16-2548. Epub 2017 Feb 16.

12.

Design, synthesis and evaluation of anti-CD123 antibody drug conjugates.

Li B, Zhao W, Zhang X, Wang J, Luo X, Baker SD, Jordan CT, Dong Y.

Bioorg Med Chem. 2016 Nov 15;24(22):5855-5860. doi: 10.1016/j.bmc.2016.09.043. Epub 2016 Sep 17.

13.

E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia.

Park IK, Blum W, Baker SD, Caligiuri MA.

Leukemia. 2017 Feb;31(2):502-505. doi: 10.1038/leu.2016.293. Epub 2016 Oct 24. No abstract available.

14.

Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation.

Drenberg CD, Buelow DR, Pounds SB, Wang YD, Finkelstein D, Rahija RJ, Shurtleff SA, Rubnitz JE, Inaba H, Gruber TA, Klco JM, Baker SD.

Leuk Lymphoma. 2017 Jan;58(1):247-250. Epub 2016 Jun 1. No abstract available.

15.

Evaluation of artemisinins for the treatment of acute myeloid leukemia.

Drenberg CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, Baker SD.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1231-43. doi: 10.1007/s00280-016-3038-2. Epub 2016 Apr 28.

16.

Corrigendum to "Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography" [J. Chromatogr. B 813(1) (2004) 81-88].

Zhao M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker SD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 May 1;1020:167. doi: 10.1016/j.jchromb.2016.03.018. Epub 2016 Mar 25. No abstract available.

PMID:
27063482
17.

Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.

Edginton AN, Zimmerman EI, Vasilyeva A, Baker SD, Panetta JC.

Cancer Chemother Pharmacol. 2016 May;77(5):1039-52. doi: 10.1007/s00280-016-3018-6. Epub 2016 Apr 6.

18.

Improving Sepsis Recognition and Utilization of Early Goal-Directed Therapy in the Prehospital Environment: A Review of the Literature.

Baker SD.

J Emerg Nurs. 2016 Sep;42(5):387-94. doi: 10.1016/j.jen.2016.02.015. Epub 2016 Mar 28. Review. No abstract available.

PMID:
27033336
19.

A phosphotyrosine switch regulates organic cation transporters.

Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N.

Nat Commun. 2016 Mar 16;7:10880. doi: 10.1038/ncomms10880.

20.

Pregnant Women's Infant Oral Health Knowledge and Beliefs: Influence of Having Given Birth and of Having a Child in the Home.

Baker SD, Quiñonez RB, Boggess K, Phillips C.

Matern Child Health J. 2016 Jun;20(6):1288-95. doi: 10.1007/s10995-016-1930-3.

PMID:
26961141
21.

ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression.

Drenberg CD, Hu S, Li L, Buelow DR, Orwick SJ, Gibson AA, Schuetz JD, Sparreboom A, Baker SD.

Clin Transl Sci. 2016 Feb;9(1):51-9. doi: 10.1111/cts.12366. Epub 2016 Feb 4.

22.

Engaging Active Bystanders in Mass Casualty Events and Other Life-Threatening Emergencies: A Pilot Training Course Demonstration.

Smith TO, Baker SD, Roberts K, Payne SA.

Disaster Med Public Health Prep. 2016 Apr;10(2):286-92. doi: 10.1017/dmp.2015.177. Epub 2016 Feb 4.

PMID:
26841861
23.

Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.

Zimmerman EI, Gibson AA, Hu S, Vasilyeva A, Orwick SJ, Du G, Mascara GP, Ong SS, Chen T, Vogel P, Inaba H, Maitland ML, Sparreboom A, Baker SD.

Cancer Res. 2016 Jan 1;76(1):117-26. doi: 10.1158/0008-5472.CAN-15-0694. Epub 2015 Dec 17.

24.

Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia.

Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD.

Clin Pharmacol Ther. 2016 Jun;99(6):651-60. doi: 10.1002/cpt.315. Epub 2016 Feb 20.

25.

Clinical significance of in vivo cytarabine-induced gene expression signature in AML.

Lamba JK, Pounds S, Cao X, Crews KR, Cogle CR, Bhise N, Raimondi SC, Downing JR, Baker SD, Ribeiro RC, Rubnitz JE.

Leuk Lymphoma. 2016;57(4):909-20. doi: 10.3109/10428194.2015.1086918. Epub 2015 Oct 16.

26.

Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.

Vasilyeva A, Durmus S, Li L, Wagenaar E, Hu S, Gibson AA, Panetta JC, Mani S, Sparreboom A, Baker SD, Schinkel AH.

Cancer Res. 2015 Jul 1;75(13):2729-36. doi: 10.1158/0008-5472.CAN-15-0280. Epub 2015 May 7.

27.

Fuzzing: a solution chosen by the FDA to investigate detection of software vulnerabilities.

Baker SD.

Biomed Instrum Technol. 2014 Spring;Suppl:42-7. doi: 10.2345/0899-8205-48.s1.42. No abstract available.

PMID:
24848149
28.

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.

Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A.

Br J Cancer. 2014 Feb 18;110(4):894-8. doi: 10.1038/bjc.2013.811. Epub 2014 Jan 7. Erratum in: Br J Cancer. 2017 Jul 13;:.

29.

Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

Nies AT, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M, Pott C, Hofmann U, Volk C, Hu S, Baker SD, Sparreboom A, Ruth P, Koepsell H, Schwab M.

Clin Cancer Res. 2014 Feb 15;20(4):985-94. doi: 10.1158/1078-0432.CCR-13-1999. Epub 2013 Dec 18.

30.

Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.

Xie C, Drenberg C, Edwards H, Caldwell JT, Chen W, Inaba H, Xu X, Buck SA, Taub JW, Baker SD, Ge Y.

PLoS One. 2013 Nov 11;8(11):e79106. doi: 10.1371/journal.pone.0079106. eCollection 2013.

31.

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD.

Blood. 2013 Nov 21;122(22):3607-15. doi: 10.1182/blood-2013-07-513044. Epub 2013 Sep 17.

32.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H.

Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.

33.

Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.

Furmanski BD, Hu S, Fujita KI, Li L, Gibson AA, Janke LJ, Williams RT, Schuetz JD, Sparreboom A, Baker SD.

Clin Cancer Res. 2013 Aug 15;19(16):4359-4370. doi: 10.1158/1078-0432.CCR-13-0980. Epub 2013 Jun 21.

34.

Alternative formulations of sorafenib for use in children.

Navid F, Christensen R, Inaba H, Li L, Chen Z, Cai X, Regel J, Baker SD.

Pediatr Blood Cancer. 2013 Oct;60(10):1642-6. doi: 10.1002/pbc.24619. Epub 2013 Jun 20.

35.

Security and safety for medical devices and hospitals.

Baker SD, Knudsen J, Ahmadi DM.

Biomed Instrum Technol. 2013 May-Jun;47(3):208-11. doi: 10.2345/0899-8205-47.3.208. No abstract available.

PMID:
23692103
36.

Students entering internship show readiness in the nutrition care process.

Baker SD, Cotugna N.

J Hum Nutr Diet. 2013 Oct;26(5):512-8. doi: 10.1111/jhn.12107. Epub 2013 May 11.

PMID:
23662593
37.

Pediatric hydrocarbon-related injuries in the United States: 2000-2009.

Jolliff HA, Fletcher E, Roberts KJ, Baker SD, McKenzie LB.

Pediatrics. 2013 Jun;131(6):1139-47. doi: 10.1542/peds.2012-3913. Epub 2013 May 6.

PMID:
23650296
38.

Characterization of the spectrum of hemodynamic profiles in trauma patients with acute neurogenic shock.

Summers RL, Baker SD, Sterling SA, Porter JM, Jones AE.

J Crit Care. 2013 Aug;28(4):531.e1-5. doi: 10.1016/j.jcrc.2013.02.002. Epub 2013 Apr 6.

39.

Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.

Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, Onar-Thomas A, Panetta JC, Chin TK, Merchant TE, Baker JN, Kaste SC, Gajjar A, Stewart CF.

Clin Cancer Res. 2013 Jun 1;19(11):3050-8. doi: 10.1158/1078-0432.CCR-13-0306. Epub 2013 Mar 27.

40.

Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.

Drenberg CD, Baker SD, Sparreboom A.

Clin Pharmacol Ther. 2013 Mar;93(3):215-9. doi: 10.1038/clpt.2012.247.

PMID:
23419484
41.

Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.

Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A, Baker SD.

Clin Cancer Res. 2013 Mar 15;19(6):1458-66. doi: 10.1158/1078-0432.CCR-12-3306. Epub 2013 Jan 22.

42.

Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, Davidoff AM, Spunt SL, Furman WL, McGregor LM, Hu S, Panetta JC, Turner D, Fofana D, Reddick WE, Leung W, Santana VM.

Clin Cancer Res. 2013 Jan 1;19(1):236-46. doi: 10.1158/1078-0432.CCR-12-1897. Epub 2012 Nov 8. Erratum in: Clin Cancer Res. 2013 Apr 1;19(7):1914.

43.

OATP1B1 polymorphism as a determinant of erythromycin disposition.

Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, Hu S, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A.

Clin Pharmacol Ther. 2012 Nov;92(5):642-50. doi: 10.1038/clpt.2012.106. Epub 2012 Sep 19.

44.

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.

Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A.

Br J Cancer. 2012 Sep 25;107(7):1100-6. doi: 10.1038/bjc.2012.357. Epub 2012 Aug 28.

45.

Ontogeny and sorafenib metabolism.

Zimmerman EI, Roberts JL, Li L, Finkelstein D, Gibson A, Chaudhry AS, Schuetz EG, Rubnitz JE, Inaba H, Baker SD.

Clin Cancer Res. 2012 Oct 15;18(20):5788-95. doi: 10.1158/1078-0432.CCR-12-1967. Epub 2012 Aug 27.

46.

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A.

Clin Cancer Res. 2012 Aug 15;18(16):4433-40. Epub 2012 Jun 18.

47.

Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.

de Graan AJ, Loos WJ, Friberg LE, Baker SD, van der Bol JM, van Doorn L, Wiemer EA, van der Holt B, Verweij J, Mathijssen RH.

Clin Cancer Res. 2012 Aug 15;18(16):4425-32. doi: 10.1158/1078-0432.CCR-12-0728. Epub 2012 May 29.

48.

Inhibition of OCTN2-mediated transport of carnitine by etoposide.

Hu C, Lancaster CS, Zuo Z, Hu S, Chen Z, Rubnitz JE, Baker SD, Sparreboom A.

Mol Cancer Ther. 2012 Apr;11(4):921-9. doi: 10.1158/1535-7163.MCT-11-0980. Epub 2012 Mar 2.

49.

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, Heym KM, Christensen R, Onciu M, Shurtleff SA, Pounds SB, Pui CH, Ribeiro RC, Campana D, Baker SD.

J Clin Oncol. 2011 Aug 20;29(24):3293-300. doi: 10.1200/JCO.2011.34.7427. Epub 2011 Jul 18.

50.

Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, Yang S, Pounds S, Fan Y, Calabrese C, Rehg JE, Campana D, Rubnitz JE, Baker SD.

J Natl Cancer Inst. 2011 Jun 8;103(11):893-905. doi: 10.1093/jnci/djr107. Epub 2011 Apr 12.

Supplemental Content

Loading ...
Support Center